Burden of Disease

Onset of stage 3 aT1D at a younger age  is associated with increased CVD risk and early mortality.⁴

Lifelong management of aT1D drives significant increases in both direct (HCRU)  and indirect costs (productivity loss, caregiver burden).⁵

GULF:
One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE .
For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number.
For all Gulf countries ✆ +971 45 50 38 63 or email: medical-information.gulf@sanofi.com.
Full prescribing information is available upon request.
To Report adverse events please call: +971 561747001 or email Gulf.Pharmacovigilance@sanofi.com
www.sanofi.com

KSA:
To report any side effect(s):
Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC
SFDA call center: 19999 • E-mail: npc.drug@sfda.gov.sa • Website: https://ade.sfda.gov.sa/
Full Prescribing Information is available upon request: SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A.
Tel: +966-12-669-3318, Fax: +966-12-663-6191
For Medical Information, please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com
For Pharmacovigilance, please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any Product Technical Complaint, please contact SANOFI Quality Department:
Email: quality.greatergulf@Sanofi.com ,  www.sanofi.com.sa